-
Posted by
Two Blokes Jul 18 -
Filed in
Stock
-
2 views
ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat expectations, with YoY growth rising to its highest point in 3 years, earnings merely met estimates, disappointing given the company's history of bottom-line beats averaging 9%. ABT's second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin guidance was cut, despite the company facilitating 100bps of improvements in Q2.
